osteoporosis-treatment-market

Osteoporosis Treatment Market By Drug Type (Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors) - Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

13 Aug 2017 Format PDF icon PPT icon XLS icon Request Sample

Osteoporosis is a commonly observed bone disease that weakens bone and further enhance the risk of bone breaking. This condition makes bone fragile thus increasing the susceptibility of fracture. According to International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. Thus with rising prevalence of osteoporosis, number of campaigns and programs are conducted by National Osteoporosis Foundation (NOF), National Bone Health Alliance and Fracture Liaison Service (FLS) to increase in awareness about osteoporosis amongst healthcare professionals and individual, which would further propel the osteoporosis treatment market. With novel drug in pipeline, entry of generic especially in emerging economies is anticipated to boost the demand of osteoporosis treatment market in the forecast period.

The report titled “Osteoporosis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the overall osteoporosis treatment market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drug and different geographies. The drug types studied for analyzing the overall global osteoporosis treatment market are majorly segmented into bisphosphonates, parathyroid hormone therapy, calcitonin, selective estrogen inhibitors modulator (SERM) and rank ligand inhibitors.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global osteoporosis treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global osteoporosis treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global osteoporosis treatment market. In-depth competitive environment analysis and historical (2021) market size data are also provided in the report.

Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Allergan Plc., Amgen, Inc., Actavis Plc., Eli Lilly and Company, F.Hoffmann La Roche Ltd, GlaxoSmithKline Pharmaceutical Ltd, Merck & Co AG, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd.. and others.

Bisphosphonates is the most commonly prescribed medication for prevention and treatment of osteoporosis. It occupies the major revenue share, thus dominating the global osteoporosis treatment market due to its wide consumption, attributing to high efficacy. High adoption of new drug classes such as rank ligand inhibitors and parathyroid hormone therapy, further boosts the growth of osteoporosis treatment market. With the entry of novel drug class, hurdles such as chronic and generics side effects of the established drugs will be overcome. The entry of generic drugs, especially in developing countries, will help in addressing the clinical need for low cost medication for treatment of osteoporosis, which further would exhibit lucrative growth in forecast period.

In 2021, North America dominated the global osteoporosis treatment market followed by Europe. Currently, in U.S., osteoporosis and low bone mass are considered as major public health threat affecting around 44 million U.S. women and men aged 50 and older. In Canada, osteoporosis affects approximately 1.4 million individuals, mainly postmenopausal women and the elderly. Primarily due to geriatric population, the prevalence of osteoporosis and low bone mass is expected to increase, thus driving the osteoporosis treatment market. Asia Pacific is anticipated to be the fastest growing regional market in the forecast period 2017-2025. In Asia, high portion of population with osteoporosis remains underdiagnosed and undertreated, even in the most high risk patients who have already had a fracture. This situation is commonly observed in rural areas. In developing countries such as India and China, majority of the population lives in rural areas (60% in China), home care treatment are more preferred over surgical treatment in hospitals even in case of hip fractures. But with rising awareness, improving healthcare structure, and increasing population in emerging economies will drive the growth of osteoporosis treatment market.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Osteoporosis Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Osteoporosis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Drug
  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Calcitonin
  • Selective Estrogen Inhibitors Modulator (SERM)
  • Rank Ligand Inhibitors

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Osteoporosis Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Osteoporosis Treatment market?
  • Which is the largest regional market for Osteoporosis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Osteoporosis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Osteoporosis Treatment market worldwide?
Choose Licence Type
$4325
$6325
$12650
Why Acute
View Other Reports